Progress in HBeAg-negative chronic hepatitis B therapy
This article has no abstract so we have provided the first paragraph of the full text.
Responding to the high relapse rates associated with current therapies, Marcellin et al. have compared the efficacy and safety of peginterferon alfa-2a monotherapy, peginterferon alfa-2a plus lamivudine, and lamivudine monotherapy in the treatment of HBeAg-negative chronic hepatitis B.
Full text of this article is available with one of the following:
- Membership of the American College of Gastroenterology. If already a member, please login.
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Chemical biology Dressed-up proteinsNature News and Views (26 Apr 2007)
Mal-function of TLRs by SOCSNature Immunology News and Views (01 Feb 2006)
See all 3 matches for News And Views